RxDoctor Payments Data

Charles Balbuena Heath, MD

General Practice · Green Cove Springs, FLNPI 1851389076

Payments from drug & device makers

$475in general payments, 2019–2025

Across 19 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$168
  • Exact Sciences$96
  • AbbVie$46
  • Lilly USA, LLC$46
  • Amgen$33
  • Insulet Corporation$23
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475 in reported general payments places this provider in the 60th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$330
Medicare patients
22
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$76,758
JardianceEmpagliflozin43$32,863
TrulicityDulaglutide16$29,009
EliquisApixaban15$16,454
XareltoRivaroxaban11$16,194
Humalog Kwikpen U-100Insulin Lispro12$6,439
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,445
VascepaIcosapent Ethyl13$4,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,866
Atorvastatin Calcium253$1,836
Albuterol Sulfate HfaAlbuterol Sulfate61$1,629
Gabapentin137$1,521
Levothyroxine Sodium111$1,206
Amlodipine Besylate163$1,021
Ondansetron Hcl26$903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$76,75880 claims
Lilly USA, LLCTrulicity$46$29,00916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,901 general practice providers in Florida.

Other general practice in Green Cove Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →